|
**Overview**: Interleukin-6 Mini Panel**Introduction**: The Interleukin-6 Mini Panel is a diagnostic tool designed to assess inflammatory response using serum samples. In India, elevated IL-6 is a key marker in acute infections, sepsis, autoimmune diseases (RA, SLE), COVID-19 severity, and malignancies, correlating with cytokine storm and poor outcomes. High morbidity from under-testing in rural/low-SES patients with fever of unknown origin or critical illness, limited cytokine labs, delayed targeted therapy (tocilizumab in select cases) leading to multi-organ failure. Per immunology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for IL-6 level and CRP over 1-2 days with high sensitivity, valuable for monitoring inflammation severity and response to treatment. This diagnostic falls under inflammatory screening and targets patients with suspected systemic inflammation, sepsis, or autoimmune flare, addressing accurate detection to guide anti-IL-6 therapy or supportive care. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise cytokine assessment and reducing mortality in inflammatory conditions. Its serum-based approach ensures reliable biomarker quantification.**Other Names**: IL-6 Mini Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: IL-6 + CRP panel standard; in India, expanded post-COVID.**Purpose**: The test assesses 2 parameters including IL-6 level to guide inflammatory response evaluation, assess severity, inform therapy.**Test Parameters**: 1. IL-6 Level, 2. CRP.**Pretest Condition**: No fasting required; patients should report fever or inflammatory symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on fever, joint pain, infection suspicion.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected inflammation including organ failure, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or diurnal variation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated IL-6 + CRP indicates severe inflammation, necessitating specialist input.**Specialist Consultation**: Rheumatologists or intensivists should be consulted for management.**Additional Supporting Tests**: Procalcitonin, ferritin for confirmation.**Test Limitations**: Nonspecific marker; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Inflammation Studies India 2023. |
